Drug Type TCR-T Cell therapy |
Synonyms CRTE7A2-01 TCR-T Cell(Corregene Biotechnology), CRTE7A2, CRTE7A2 01 + [1] |
Target |
Action inhibitors |
Mechanism E7 inhibitors(HPV E7 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HPV16 positive solid tumors | Phase 1 | China | 17 Apr 2024 | |
| Nasopharyngeal Carcinoma | Phase 1 | China | 17 Apr 2024 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | China | 17 Apr 2024 | |
| Advanced cancer | Phase 1 | - | 15 Apr 2024 | |
| Metastatic Carcinoma to the Uterine Cervix | Phase 1 | - | 15 Apr 2024 | |
| Nasopharyngeal Neoplasms | Phase 1 | - | 15 Apr 2024 | |
| Squamous cell carcinoma of head and neck metastatic | Phase 1 | - | 15 Apr 2024 | |
| Anus Neoplasms | Phase 1 | China | 17 Jul 2022 | |
| Uterine Cervical Cancer | Phase 1 | China | 17 Jul 2022 |





